Today's Rundown Novartis pivots Shanghai R&D site from early discovery to development Struggling Alkermes spends $950M sculpting Rodin buyout AHA: Analysis counters concerns about Amgen heart failure drug Bayer, Merck's vericiguat hits endpoint in heart failure phase 3 AHA: Caladrius single injection helps heart disease that hits women the hardest Novo Nordisk taps Dicerna’s RNAi tech in $225M metabolic, liver disease deal AHA: MedCo's PCSK9 rival inclisiran hits LDL AHA: Janssen drops clinical sites for smartphones, wearables in 100% virtual Invokana study AHA: Amarin's Vascepa halts progression of arterial plaque in key study Featured Story | | | Monday, November 18, 2019 Novartis is calling it curtains on early drug discovery at its R&D site in Shanghai in a companywide move to “rebalance” its discovery and early development efforts. The company plans to add more than 300 new jobs but will be bidding adieu to about 150 early discovery personnel. |
|
|---|
|
Top Stories Monday, November 18, 2019 Just a month ago, Alkermes was announcing it was slashing scores of jobs; now, it’s willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics. Monday, November 18, 2019 Amgen has found no evidence that heart failure drug omecamtiv mecarbil hampers diastolic function in a post hoc analysis of phase 2 data. The finding may quell concerns that the effect of the cardiac myosin activator on the cardiac cycle will have negative side effects on diastolic filling times. Monday, November 18, 2019 A phase 3 trial of Bayer and Merck’s vericiguat in heart failure patients has met its primary endpoint. The top-line readout appears to justify the risk the partners took when they moved the stimulator of the soluble guanylate cyclase enzyme into phase 3 despite missing the mark in an earlier trial. Monday, November 18, 2019 We tend to think of heart disease and heart disorders to be, in the main, things that affect men more than women, but this is of course not true. Monday, November 18, 2019 Novo Nordisk is betting $225 million on Dicerna’s RNAi platform in an R&D collaboration focused on liver-related diseases and conditions, including nonalcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. It is promising another $75 million in near-term cash, as well as hundreds of millions in milestones in the heavily backloaded deal. Monday, November 18, 2019 The Medicines Company has posted more late-phase data linking its siRNA inclisiran to steep declines in LDL cholesterol. Inclisiran achieved a placebo-adjusted drop in LDL cholesterol of 58%, although it failed to drive the positive changes in cardiovascular outcomes seen in an earlier study. Saturday, November 16, 2019 Johnson & Johnson’s pharmaceutical arm Janssen is launching its first completely virtual clinical trial, using personal smartphones and wearable devices to track participants with no in-person site visits required. Sunday, November 17, 2019 PHILADELPHIA—With an FDA decision to expand Amarin's Vascepa label to include cardiovascular risk reduction looming, a new imaging study shows the drug could have an effect on stopping the progression of plaque in the arteries. That could help explain Vascepa's game-changing CV outcomes. Enrollment Showcase Resources Sponsored by: Outer Edge Technology, LLC See why visionaries outsource the design and management of the infrastructure allowing their scientists to innovate. Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2020 January 14, 2020 | The Fairmont Hotel | San Francisco, CA A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 